Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Niki Katsiki, Kyriakos Kazakos & Filippos Triposkiadis. (2022) Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 23:17, pages 1957-1974.
Read now
Read now
Claudio Napoli, Paola Bontempo, Vittorio Palmieri, Enrico Coscioni, Ciro Maiello, Francesco Donatelli & Giuditta Benincasa. (2021) Epigenetic Therapies for Heart Failure: Current Insights and Future Potential. Vascular Health and Risk Management 17, pages 247-254.
Read now
Read now
Srikanth Yandrapalli, George Jolly, Adam Horblitt, Abdallah Sanaani & Wilbert S. Aronow. (2017) Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgraduate Medicine 129:8, pages 811-821.
Read now
Read now
Articles from other publishers (21)
Viveca Ritsinger, Emil Hagström, Kristina Hambraeus, Stefan James, Tomas Jernberg, Bo Lagerqvist, Margrét Leosdottir, Pia Lundman, John Pernow, Ollie Östlund & Anna Norhammar. (2023) Design and rationale of the myocardial infarction and new treatment with metformin study (MIMET) - Study protocol for a registry-based randomised clinical trial. Journal of Diabetes and its Complications 37:10, pages 108599.
Crossref
Crossref
Richard Francoeur. (2021) Multimorbidity from Diabetes, Heart Failure, and Related Conditions: Assessing a Panel of Depressive Symptoms as Both Formative and Reflective Indicators of a Latent Trait. Mathematics 9:21, pages 2715.
Crossref
Crossref
Niki Katsiki, Ele Ferrannini & Christos Mantzoros. (2020) New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism 107, pages 154218.
Crossref
Crossref
Silvia Sciannimanico, Franco Grimaldi, Fabio Vescini, Giovanni De Pergola, Massimo Iacoviello, Brunella Licchelli, Edoardo Guastamacchia, Vito A. Giagulli & Vincenzo Triggiani. (2020) Metformin: Up to Date. Endocrine, Metabolic & Immune Disorders - Drug Targets 20:2, pages 172-181.
Crossref
Crossref
Nina A. Petunina, Ivan V. Trukhin, Liubov V. Trukhina, Zhanna M. Sizova & Valeria L. Zakharova. (2019) Heart failure and diabetes mellitus: insight into comorbidity. Diabetes mellitus 22:1, pages 79-87.
Crossref
Crossref
Veronika Piskovatska, Nadiya Stefanyshyn, Kenneth B. Storey, Alexander M. Vaiserman & Oleh Lushchak. (2018) Metformin as a geroprotector: experimental and clinical evidence. Biogerontology 20:1, pages 33-48.
Crossref
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
Crossref
Veronika Piskovatska, Olha Strilbytska, Alexander Koliada, Alexander Vaiserman & Oleh Lushchak. 2019. Biochemistry and Cell Biology of Ageing: Part II Clinical Science. Biochemistry and Cell Biology of Ageing: Part II Clinical Science
339
392
.
Marc E. De Broe, Farshad Kajbaf & Jean-Daniel Lalau. (2018) Renoprotective Effects of Metformin. Nephron 138:4, pages 261-274.
Crossref
Crossref
Abdulhalim Jamal Kinsara & Yasser Mansour Ismail. (2018) Metformin in heart failure patients. Indian Heart Journal 70:1, pages 175-176.
Crossref
Crossref
Lyudmila A. Ruyatkina & Dmitriy S. Ruyatkin. (2017) Multidimensional effects of metformin in patients with type 2 diabetes. Diabetes mellitus 20:3, pages 210-219.
Crossref
Crossref
Gregory J. Salber, Yu-Bo Wang, John T. Lynch, Karen M. Pasquale, Thiruchandurai V. Rajan, Richard G. Stevens, James J. Grady & Anne M. Kenny. (2017) Metformin Use in Practice: Compliance With Guidelines for Patients With Diabetes and Preserved Renal Function. Clinical Diabetes 35:3, pages 154-161.
Crossref
Crossref
Marion Lepelley, Joris Giai, Nassima Yahiaoui, Sébastien Chanoine & Céline Villier. (2016) Lactic Acidosis in Diabetic Population: Is Metformin Implicated? Results of a Matched Case-Control Study Performed on the Type 2 Diabetes Population of Grenoble Hospital University. Journal of Diabetes Research 2016, pages 1-8.
Crossref
Crossref
I. Vasiliadis, G. Kolovou, S. Mavrogeni, D.R. Nair & D.P. Mikhailidis. (2014) Sudden cardiac death and diabetes mellitus. Journal of Diabetes and its Complications 28:4, pages 573-579.
Crossref
Crossref
Running Hamid Nasri. (2013) Renoprotective effects of metformin. DARU Journal of Pharmaceutical Sciences 21:1.
Crossref
Crossref
Lilian Beatriz Aguayo Rojas & Marilia Brito Gomes. (2013) Metformin: an old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome 5:1.
Crossref
Crossref
Stavroula A Paschou & Richard David Leslie. (2013) Personalizing guidelines for diabetes management: twilight or dawn of the expert?. BMC Medicine 11:1.
Crossref
Crossref
Daryn K. Norwood, Allison A. Chilipko, Shril M. Amin, David Macharia & Kimberly L. Still. (2013) Evaluating the Potential Benefits of Metformin in Patients with Cardiovascular Disease and Heart Failure. The Consultant Pharmacist 28:9, pages 579-583.
Crossref
Crossref
. (2013) Current World Literature. Current Opinion in Cardiology 28:3, pages 369-379.
Crossref
Crossref
A.J. Scheen & N. Paquot. (2013) Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes. Diabetes & Metabolism 39:3, pages 179-190.
Crossref
Crossref
Bogdan Wiliński, Jerzy Wiliński, Eugeniusz Somogyi, Joanna Piotrowska & Włodzimierz Opoka. (2013) Metformin raises hydrogen sulfide tissue concentrations in various mouse organs. Pharmacological Reports 65:3, pages 737-742.
Crossref
Crossref